An Intermediate Expanded Use Trial of DFMO
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 26, 2018
CompletedFirst Posted
Study publicly available on registry
July 10, 2018
CompletedFebruary 20, 2026
February 1, 2026
June 26, 2018
February 18, 2026
Conditions
Interventions
In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS.
Eligibility Criteria
You may qualify if:
- Age: 0-30 years at the time of initial diagnosis.
- Diagnosis: Histologic verification at either the time of original diagnosis or a previous relapse of High Risk neuroblastoma, medulloblastoma, atypical teratoid rhabdoid tumor, embryonal tumor with abundant neuropil and true rosettes, ependymoblastoma, medulloepithelioma and other rare pediatric MYC, ODC or LIN28/Let7 driven tumors (each type will form a new subset).
- Disease Status: Subjects must be in one of the following disease categories:
- High risk neuroblastoma patients that have completed standard of care upfront therapy and are not eligible for NMTRC014.
- Medulloblastoma patients who have completed standard of care therapies.
- Relapsed/refractory neuroblastoma patients who have completed standard of care therapies.
- Rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase who have completed standard of care therapies.
- Subjects are not eligible to enroll on DFMO studies NMTRC002, NMTRC003, NMTRC010, or NMTRC014.
- A negative serum or urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ≥13 years of age).
- Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
- Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
You may not qualify if:
- BSA (m2) of \<0.25
- Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Giselle Shollerlead
- K C Pharmaceuticals Inc.collaborator
- USWM, LLCcollaborator
Study Sites (1)
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania, 17033, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Giselle Sholler, MD
Beat Childhood Cancer
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Study Chair
Study Record Dates
First Submitted
June 26, 2018
First Posted
July 10, 2018
Last Updated
February 20, 2026
Record last verified: 2026-02